New York, NY -- (SBWIRE) -- 01/23/2014 -- PennyStockChronicle covers the breadth of the markets, from NASDAQ, NYSE, AMEX, ETF, Penny Stocks, Emerging Markets, activities at the Fed and more. PennyStockChronicle brings you the most vibrant coverage of following stocks: DURECT Corporation (NASDAQ:DRRX), Endeavour Silver Corp (NYSE:EXK), Antares Pharma Inc (NASDAQ:ATRS), Liberator Medical Holdings Inc (NYSEMKT:LBMH)
DURECT Corporation (NASDAQ:DRRX) showed a volume of 1.41 million shares by the end of last trade whereas the average volume of the stock remained 953,962 shares. The stock opened the session at $2.12 but then moved to $2.12. At that price, the stock showed a positive performance of 0.47%. Durect Corporation is a specialty pharmaceutical company focused on the development of pharmaceutical products based on its drug delivery technology platforms. The Company’s product pipeline, as of December 31, 2012, consisted of eight investigational drug candidates in clinical development,
Will DRRX Continue To Move Higher? Find Out Here
Endeavour Silver Corp (NYSE:EXK) opened the session at $4.45 and closed the session at $4.32. The stock showed a negative performance of -2.92% in previous trading session. Traded with volume of 1.38 million shares in the prior session and the average volume of the stock remained 1.30 million shares. Endeavour Silver Corp. (Endeavour) is engaged in the evaluation, acquisition, exploration, development and exploitation of silver mining properties in Mexico and in exploration in Chile. The Company’s producing mines include Guanacevi mine, Bolanitos Mine and El Cubo.
Has EXK Found The Bottom And Ready To Gain Momentum? Find Out Here
Antares Pharma Inc (NASDAQ:ATRS) opened the session at $4.96 and closed the session at $4.79. The stock showed a negative performance of -3.23% in previous trading session. Traded with volume of 1.38 million shares in the prior session and the average volume of the stock remained 1.51 million shares. The beta of the stock remained 0.14. Antares Pharma, Inc. (Antares) is a pharma company that focuses on self-injection pharmaceutical products and technologies and topical gel-based products. The Company’s subcutaneous and intramuscular injection technology platforms include Vibex disposable pressure-assisted auto injectors, Vision reusable needle-free injectors,
Why Should Investors Buy ATRS After the Recent Fall? Just Go Here and Find Out
Liberator Medical Holdings Inc (NYSEMKT:LBMH) the stock advanced 7.05% and finished the session at $50.1. Traded with volume of 1.38 million shares in the prior session and the average volume of the stock remained 796,493.00 shares. The beta of the stock remained 1.18. Liberator Medical Holdings, Inc. is a national direct-to-consumer provider of medical supplies to Medicare-eligible seniors. The Company’s wholly owned subsidiary, Liberator Medical Supply, Inc. (LMS), is a direct-to-consumer, provider of Medicare Part B Benefits. LMS has four main product lines: diabetes, urological, ostomy and mastectomy.
Will LBMH Continue To Move Higher? Find Out Here
Penny Stock Chronicle is comprised of a team of vetted penny stock traders who’ve been trading since 2008 & have developed the skills needed to trade for consistent profits.
PLEASE NOTE WELL: The employees of PennyStockChronicle.com are not registered as Investment Advisors in any jurisdiction whatsoever. Never invest in any stock featured on our site or emails unless you can afford to lose your entire investment. Investing in “penny stocks” is highly speculative.
Verify all claims and do your own due diligence on all securities. PennyStockChronicle.com profiles are not a solicitation or recommendation to buy, sell or hold securities. PennyStockChronicle.com is not offering securities for sale. Neither PennyStockChronicle.com nor its owners, operators, affiliates or anyone disseminating information on its behalf is registered as an Investment Advisor under any federal or state law and none of the information provided by PennyStockChronicle.com, its owners, operators, affiliates or anyone disseminating information on its behalf should be construed as investment advice or investment recommendations. PennyStockChronicle.com does not recommend that the securities profiled should be purchased, sold or held.
Read Full Disclaimer at: http://pennystockchronicle.com/disclaimer
Copyright © 2005-2014 - SBWire, The Small Business Newswire - All Rights Reserved - Important Disclaimer
Contact Us: 888-4-SBWIRE (US) - 920-593-5640 (International)